Mitsubishi UFJ Asset Management Co. Ltd. Lowers Stake in Smith & Nephew SNATS, Inc. $SNN

Mitsubishi UFJ Asset Management Co. Ltd. lowered its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 15.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,901 shares of the medical equipment provider’s stock after selling 2,380 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Smith & Nephew SNATS were worth $395,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Richards Merrill & Peterson Inc. increased its stake in Smith & Nephew SNATS by 500.0% during the 1st quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 1,000 shares during the period. Banque Transatlantique SA bought a new stake in Smith & Nephew SNATS in the first quarter valued at about $52,000. Bessemer Group Inc. raised its position in shares of Smith & Nephew SNATS by 111.9% during the 2nd quarter. Bessemer Group Inc. now owns 3,709 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 1,959 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of Smith & Nephew SNATS by 15.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,149 shares of the medical equipment provider’s stock worth $118,000 after purchasing an additional 541 shares during the period. Finally, Brooklyn Investment Group lifted its holdings in Smith & Nephew SNATS by 3,086.3% in the first quarter. Brooklyn Investment Group now owns 4,429 shares of the medical equipment provider’s stock worth $126,000 after acquiring an additional 4,290 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on SNN shares. Royal Bank Of Canada restated an “outperform” rating on shares of Smith & Nephew SNATS in a research note on Monday, October 20th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 3rd. Sanford C. Bernstein set a $37.50 target price on shares of Smith & Nephew SNATS and gave the stock a “market perform” rating in a report on Tuesday, October 14th. Finally, Canaccord Genuity Group lowered their price target on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $35.75.

Smith & Nephew SNATS Stock Performance

NYSE SNN opened at $32.72 on Friday. Smith & Nephew SNATS, Inc. has a twelve month low of $23.69 and a twelve month high of $38.79. The stock has a 50-day simple moving average of $36.03 and a 200 day simple moving average of $33.02. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.